Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | DRD3 | P35462 | 2/20 | 0.45 |
| ▸ | HTR1A | P08908 | 3/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4827565 | 0.95 | DRD2 (0.53) | DRD2SIGMAR1DRD3HTR1AHTR6 | |
| SCHEMBL24489448 | 0.91 | SIGMAR1 (0.48) | DRD2SIGMAR1DRD3HTR1AALDH1A1 | |
| SCHEMBL18408688 | 0.88 | DRD2 (0.45) | DRD2SIGMAR1DRD3HTR1AHTR6 | |
| SCHEMBL17364196 | 0.83 | SIGMAR1 (0.42) | DRD2SIGMAR1HTR1AALDH1A1PKM | |
| SCHEMBL28633214 | 0.82 | SIGMAR1 (0.41) | DRD2SIGMAR1HTR1AALDH1A1PKM | |
| SCHEMBL4826031 | 0.82 | HTR1A (0.41) | DRD2SIGMAR1HTR1AALDH1A1PKM | |
| SCHEMBL17397023 | 0.79 | ALDH1A1 (0.41) | DRD2SIGMAR1HTR1AALDH1A1PKM | |
| SCHEMBL17411300 | 0.78 | HTR1A (0.51) | DRD2SIGMAR1DRD3HTR1AHTR6 | |
| SCHEMBL18412338 | 0.77 | SIGMAR1 (0.47) | SIGMAR1 | |
| SCHEMBL29363627 | 0.76 | SIGMAR1 (0.60) | DRD2SIGMAR1DRD3HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3325443-B1 | PROCESS FOR PREPARING PRIDOPIDINE | Prilenia Neurotherapeutics Ltd (IL) | 2022-06-08 | — | — | EP | disclosed |
| EP-3325443-B1 | PROCESS FOR PREPARING PRIDOPIDINE | Prilenia Neurotherapeutics Ltd (IL) | 2022-06-08 | — | — | EP | disclosed |
| US-20170022158-A1 | PROCESS FOR PREPARING PRIDOPIDINE | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2017-01-26 | — | — | US | disclosed |
| US-20170022158-A1 | PROCESS FOR PREPARING PRIDOPIDINE | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2017-01-26 | — | — | US | disclosed |
| WO-2017015609-A1 | PROCESS FOR PREPARING PRIDOPIDINE | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2017-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170022158-A1 | PROCESS FOR PREPARING PRIDOPIDINE | PDE6D, QDPR, PDE4D | DRD2 15/4885SIGMAR1 826/4885DRD3 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.